[HTML][HTML] Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model …
Methods Non-invasive risk factors of CSPH were identified via systematic review and meta-
analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new …
analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new …
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
C Liu, H You, QL Zeng, YJ Wong, B Wang… - Clinical and … - pubmed.ncbi.nlm.nih.gov
Background & aims Non-invasive models stratifying clinically significant portal hypertension
(CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in …
(CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in …
[HTML][HTML] Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model …
C Liu, H You, QL Zeng, YJ Wong, B Wang… - Clinical and Molecular …, 2024 - e-cmh.org
Methods Non-invasive risk factors of CSPH were identified via systematic review and meta-
analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new …
analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new …